Enzymatica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Enzymatica şirketinin toplam hissedar öz sermayesi SEK189.5M ve toplam borcu SEK2.5M olup, bu da borç-öz sermaye oranını 1.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK211.9M ve SEK22.5M dir.

Anahtar bilgiler

1.3%

Borç/özkaynak oranı

SEK 2.52m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 96.90m
Eşitlik	SEK 189.49m
Toplam yükümlülükler	SEK 22.45m
Toplam varlıklar	SEK 211.95m

Son finansal sağlık güncellemeleri

Recent updates

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 20

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Jul 22

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Feb 18

Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Jan 12

Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade

Jul 20

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ENZY 'nin kısa vadeli varlıkları ( SEK128.5M ) kısa vadeli yükümlülüklerini ( SEK21.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: ENZY şirketinin kısa vadeli varlıkları ( SEK128.5M ) uzun vadeli yükümlülüklerini ( SEK1.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ENZY şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ENZY 'nin borç/öz sermaye oranı son 5 yılda 4.1% seviyesinden 1.3% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ENZY şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ENZY serbest nakit akışı her yıl % 12 1.9 yıl yetecek nakit akışına sahip olacaktır.

Enzymatica Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Recent updates

Independent Director recently bought kr93k worth of stock

Third quarter 2024 earnings released

Enzymatica AB (publ) to Report Fiscal Year 2024 Results on Apr 10, 2025

Independent Chairman recently bought kr117k worth of stock

Independent Chairman recently bought kr117k worth of stock

Enzymatica AB (publ) Announces Final Results from Independent Clinical Study of Coldzyme Show Duration of Illness Lowered by Approximately 5 Days

New major risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million.

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Second quarter 2024 earnings released: kr0.08 loss per share (vs kr0.07 loss in 2Q 2023)

Independent Director recently bought kr4.6m worth of stock

Consensus EPS estimates fall by 21%, revenue upgraded

Enzymatica AB (Publ) Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 Days

Consensus revenue estimates fall by 16%

Forecast to breakeven in 2026

New major risk - Financial position

First quarter 2024 earnings released: kr0.11 loss per share (vs kr0.091 loss in 1Q 2023)

New minor risk - Shareholder dilution

Independent Director recently sold kr60k worth of stock

Enzymatica AB (publ) Announces Composition of Nomination Committee

New minor risk - Profitability

No longer forecast to breakeven

Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million.

Independent Director recently sold kr900k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings released: kr0.30 loss per share (vs kr0.45 loss in FY 2022)

Enzymatica AB (publ) to Report Fiscal Year 2023 Final Results on Apr 09, 2024

New major risk - Financial position

Enzymatica AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Consensus revenue estimates decrease by 30%

Third quarter 2023 earnings released: kr0.056 loss per share (vs kr0.085 loss in 3Q 2022)

Independent Chairman recently bought kr564k worth of stock

Enzymatica AB (publ) Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore Throat

Enzymatica AB (publ) Announces New Study

Is Enzymatica (STO:ENZY) Using Too Much Debt?

Second quarter 2023 earnings released: kr0.07 loss per share (vs kr0.10 loss in 2Q 2022)

Independent Director recently bought kr157k worth of stock

Independent Director recently bought kr157k worth of stock

Independent Chairman recently bought kr414k worth of stock

First quarter 2023 earnings released: kr0.091 loss per share (vs kr0.12 loss in 1Q 2022)

Independent Director recently sold kr1.5m worth of stock

Forecast to breakeven in 2025

Consensus revenue estimates decrease by 15%

Full year 2022 earnings released: kr0.45 loss per share (vs kr0.31 loss in FY 2021)

Enzymatica AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?

Enzymatica AB (publ) to Report Nine Months, 2023 Results on Nov 07, 2023

No longer forecast to breakeven

Third quarter 2022 earnings released

Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 74.6622 million.

Consensus forecasts updated

Second quarter 2022 earnings released

Enzymatica AB (publ) Announces New Data from an Ongoing In-Vitro Study

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Enzymatica AB's Mouth Spray to Be Launches in Turkey

Chairman recently bought kr1.7m worth of stock

Enzymatica and Sanofi Launches Mouth Spray in Mexico

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Enzymatica AB to Report Fiscal Year 2021 Final Results on Mar 31, 2022

Independent Director recently sold kr4.0m worth of stock

Now 24% undervalued after recent price drop

Estimating The Fair Value Of Enzymatica AB (STO:ENZY)

Forecast breakeven date pushed back to 2023

Chairman recently bought kr1.5m worth of stock

Director recently bought kr4.7m worth of stock

Consensus revenue estimates fall to kr82.0m

Things Look Grim For Enzymatica AB (STO:ENZY) After Today's Downgrade